The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.

Journal: BMC cancer
Published Date: Aug 25, 2025

Abstract

BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy and platinum-based chemotherapy are key components of first-line treatment for advanced Gastric or Gastroesophageal Junction (G/GEJ) cancer. However, the role of immune cells infiltrating the tumor microenvironment (TME) in predicting both therapy responses is still unclear.

Authors

  • Hui Wu
    China Medical University College of Health Management, Shenyang 110122, Liaoning Province, China.
  • Wenzhi Shu
    Zhejiang University School of Medicine, Hangzhou, China.
  • Yongfeng Ding
    School of Intelligent Manufacturing Engineering, Chongqing University of Arts and Sciences, Chongqing, China.
  • Qiong Li
    Department of Burns & Wound Care Centre, 2nd Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, 310000, Zhejiang Province, China. 2504131@zju.edu.cn.
  • Ning Li
    Department of Respiratory and Critical Care Medicine, Center for Respiratory Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
  • Qiyue Wang
    George Washington University.
  • Yinqi Chen
    Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
  • Yuejun Han
    Zhejiang University School of Medicine, Hangzhou, China.
  • Dongdong Huang
    Department of Respiratory and Critical Care Medicine, Center for Respiratory Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
  • Haiping Jiang
    State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.

Keywords

External Resources

Popular Topics
Recent Journals